AIAnnette Pulcherie Iloki-Lewis

Annette Pulcherie Iloki-Lewis

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Annette Pulcherie Iloki-Lewis has a total of 19 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Plant-Derived Flavonoids in Ocular Diseases: Redox Signaling, Neurovascular Protection, Regulated Cell Death, and Translational Frontiers

    by Judas Tadeo Vargas-Durazo, Lidianys María Lewis-Luján, Annette Pulcherie Iloki-Lewis, Juan Carlos Galvez-Ruiz, Rocio Sugih Miranda, Cinthia Jhovanna Perez-Martinez, Diego Emmanuel Guerrero-Magaña, Sayil Alejandra De La Torre-Othon, Sergio Trujillo-López, Simon Bernard Iloki-Assanga

    Flavonoids are compounds found in many plants and foods. Laboratory studies suggest that some can protect eye cells against oxidative and inflammatory injury, but these findings do not establish benefits for patients. This review examines which compounds were tested, how they act, whether they reach the eye, and how closely experimental models resemble human disease. It proposes a framework for identifying the evidence needed before selected flavonoids can be evaluated as complementary approaches to ocular care. Plant-derived flavonoids have been investigated as potential modulators of oxidative, inflammatory, and neurovascular injury in ocular diseases, but their clinical relevance remains uncertain. This narrative review critically examines the literature published from January 2016 to August 2026, supplemented by selected earlier landmark studies, to identify the evidence connecting experimental protection with plausible ocular interventions. The synthesis considers chemical identity, mechanistic support, ocular exposure, disease-model relevance, and functional outcomes. Experimental studies report modulation of antioxidant defenses, inflammatory signaling, mitochondrial homeostasis, cell survival, angiogenesis, and fibrotic remodeling. However, pathway-associated changes do not necessarily establish causal mechanisms, and protection in acute cellular or animal injury models does not establish efficacy in chronic human disease. Translation is further limited by metabolism, uncertain retinal exposure, heterogeneous preparations, and limited controlled clinical evidence. An author-proposed qualitative framework distinguishes the conclusions supported by individual findings from the additional validation required. Research priorities include standardized interventions, exposure-informed experiments, causal mechanistic studies, human-relevant models, and controlled trials with clinically meaningful outcomes. Flavonoids should therefore be regarded as candidates for further investigation as complementary interventions rather than established ocular therapeutics.

  • Open Access

    Terminalia buceras (Syn. Bucida buceras) and Retinal Oxidative Stress: A Critical Review of Published Evidence and Its Relevance to Dry Age-Related Macular Degeneration

    by Lidianys María Lewis-Luján, Annette Pulcherie Iloki-Lewis, Diego Emmanuel Guerrero-Magaña, Juan Carlos Galvez-Ruiz, Cinthia Jhovanna Perez-Martinez, Judas Tadeo Vargas-Durazo, Sergio Trujillo-López, Simon Bernard Iloki-Assanga

    Dry age-related macular degeneration (dAMD) is a multifactorial retinal disorder involving oxidative stress, mitochondrial dysfunction, chronic para-inflammation, complement dysregulation, and progressive retinal pigment epithelium (RPE) failure. This critical review evaluates the published evidence concerning Terminalia buceras (L.) C.Wright (syn. Bucida buceras L.; Combretaceae), hereafter referred to as T. buceras, and its relevance to dry age-related macular degeneration. The evidence is organized into five categories: species-specific chemical evidence, species-specific retinal evidence, species-specific non-retinal biological evidence, external isolated-compound evidence, and hypothesis-generating comparisons with related plants or experimental systems. The evidence base remains preliminary. Species-specific retinal data are restricted to in vitro observations, and there are currently no epidemiological studies linking T. buceras use to AMD outcomes, no validated animal studies demonstrating efficacy in dAMD, and no clinical studies. Moreover, phytochemical standardization, ocular exposure, metabolism, and retinal bioavailability remain insufficiently characterized. Accordingly, this review does not propose T. buceras as a preventive or therapeutic intervention and does not claim superiority over better-characterized medicinal plants. Instead, this review critically synthesizes published species-specific chemical and biological findings and evaluates their methodological limitations. The direct retinal evidence supports partial cytoprotection in an ARPE-19 oxidative-injury model, whereas the non-retinal inflammatory findings concern different preparations and experimental systems. Chemical characterization, cellular responses, and contextual mechanistic evidence are, therefore, considered separately. The available findings do not establish a disease-modifying effect on dAMD, clinically achievable retinal exposure, or chronic ocular safety.

  • Open Access

    Plant-Derived Bioactive Metabolites from the Sonoran Desert: Redox Regulation, Nrf2/NF-κB Signaling, and Emerging Therapeutic Applications

    by Lidianys Maria Lewis-Luján, Annette Pulcherie Iloki-Lewis, Diego Emmanuel Guerrero-Magaña, Mikhail A. Osadchuk, Maxim V. Trushin, Juan Carlos Galvez-Ruiz, Judas Tadeo Vargas Durazo, Cinthia Jhovanna Perez-Martinez, Maria Guadalupe Burboa-Zazueta, Ana V. Torres-Figueroa, et al.

    Plant-derived bioactive metabolites have emerged as promising modulators of oxidative stress and inflammation, two interconnected processes involved in the pathogenesis of numerous chronic diseases. Arid ecosystems, particularly the Sonoran Desert, constitute an underexplored source of structurally diverse phytochemicals with significant pharmacological potential. This review provides a comprehensive overview of major classes of plant-derived bioactives, including polyphenols, flavonoids, terpenoids, and alkaloids, with emphasis on their molecular mechanisms of antioxidant and anti-inflammatory action. These compounds exert cytoprotective effects through direct reactive oxygen species (ROS) scavenging and indirect regulation of endogenous defense systems, primarily via activation of the Nrf2/Keap1 pathway and suppression of NF-κB signaling. Additional pathways, including MAPK, PI3K/Akt, AMPK, and mitochondrial regulatory networks, are discussed as critical mediators of redox balance and inflammatory control. Particular attention is given to Sonoran Desert plant species such as Bucida buceras, Phoradendron californicum, Larrea tridentata, Opuntia spp., and Agave deserti, all of which demonstrate promising biological activities associated with enhanced adaptation to environmental stress. Experimental approaches used to evaluate phytochemical bioactivity, including chemical assays, cellular models, omics technologies, and translational strategies, are also examined. Furthermore, this review discusses current limitations related to bioavailability, phytochemical variability, and clinical validation, highlighting emerging nanodelivery systems and precision medicine approaches as potential solutions. Collectively, the evidence supports the therapeutic relevance of Sonoran Desert plant bioactives as multi-target agents for modulating oxidative stress, inflammation, and chronic disease progression.


  • Open Access

    Molecular Crosstalk of the Motilin–Somatostatin–VEGF Axis in Duodenal Dysfunction Underlying IBS-C and Functional Dyspepsia

    by Mikhail Alexander Osadchuk, Inna N. Vasil’Eva, Yuliua Krylova, Maxim M. Osadchuk, Ekaterina D. Mironova, Lidianys Maria Lewis-Luján, Annette Pulcherie Iloki-Lewis, Juan Carlos Galvez-Ruiz, Maxim Victor Trushin, Simon Bernard Iloki-Assanga

    The duodenal mucosa plays a pivotal role in gastrointestinal physiology through its endocrine cells (ECs), which secrete key regulatory factors including motilin (MLN), somatostatin (SS), and vascular endothelial growth factor (VEGF). Alterations in the expression of these mediators have been implicated in the pathogenesis of irritable bowel syndrome with constipation (IBS-C) and its overlap with functional dyspepsia (FD). In this study, immunohistochemical and morphometric analyses were performed on duodenal retrobulbar part biopsies obtained from patients with IBS-C, IBS-C combined with FD, and healthy controls. The results demonstrated a significant reduction in MLN-secreting ECs, accompanied by increased SS- and VEGF-positive ECs in IBS-C with FD patients compared to other groups. These endocrine alterations were associated with more severe abdominal pain, higher body mass index, and greater anxiety and depression scores. The findings highlight the contribution of duodenal EC dysfunction to impaired motility, visceral hypersensitivity, and low-grade inflammation, supporting the concept of the duodenum as a critical neuroendocrine hub within the gut–brain axis. This study underscores the relevance of MLN, SS, and VEGF as potential biomarkers and therapeutic targets in IBS-C and FD comorbidity.

  • Open Access

    Advances in the Molecular Pathophysiology and Emerging Therapeutic Strategies for Diabetic Retinopathy

    by Lidianys María Lewis-Luján, Diego Emmanuel Guerrero-Magaña, Annette Pulcherie Iloki-Lewis, Juan Carlos Gálvez Ruíz, Mikhail Alekseevich Osadchuk, Arsenii Alekseevich Rascheskov, Maxim Victorovich Trushin, Judas Vargas-Durazo, Cinthia Jhovanna, Simon Bernard Iloki-Assanga

    Diabetic retinopathy (DR) is a major microvascular complication of diabetes and a leading cause of vision loss in working-age adults worldwide. The pathophysiology of DR is complex and involves oxidative stress, inflammation, retinal pigment epithelium (RPE) dysfunction, and abnormal angiogenesis. Recent insights into the molecular mechanisms underlying DR have opened new avenues for targeted and personalized therapeutic strategies. In this review, we examine the advances in the understanding of oxidative damage, RPE impairment, and proangiogenic signaling in DR progression. We also highlight emerging treatment modalities, including anti-VEGF agents, gene therapy, and nutraceutical interventions. Future directions emphasize the integration of omics technologies and precision medicine approaches for individualized management. This work provides a critical synthesis of recent findings and identifies promising avenues for research and clinical intervention in DR.